Esperion Therapeutics stock remains a buy as strong drug franchises, growth, and global milestones outweigh risks. Learn more ...

Year, and Adjusted EBITDA of $11.7 Million, up 34% Year-Over YearNine Month Revenue of $135.8 Million, up 11% Year-over-Year; ...

From healthcare and mental health to education and marketing, women in AI are redefining industries with technology, ...

Greenhaven Road Capital's Q3 2025 letter analyzes a -9% return, citing no AI exposure and undervalued software holdings.

Microbix’s CEO & President, Cameron Groome, commented “Microbix regrets any impacts of international cybercrime and is continuing to improve its IT security at all levels. We appreciate the ...

Anumana, a leader in AI-powered cardiovascular diagnostics, today announced new groundbreaking clinical data presented at the American Heart Association (AHA) Scientific Sessions 2025. Among the ...

Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the ...

Detailed price information for JP Morgan Chase & Company (JPM-N) from The Globe and Mail including charting and trades.

The rapid development and integration of artificial intelligence (AI), including predictive, generative, and emerging agentic ...

The path to responsible AI in healthcare rests on solid data infrastructure, thoughtful investment and governance that ...

The specialty pharmacy industry is in a state of transformation, fueled by the rise of complex, innovative therapies and the ...

Risk stratification of patients with chest pain has traditionally focused on identifying obstructive coronary artery disease (CAD). Using this traditional approach, many symptomatic individuals are ...